HCC
GDRX icon

Hirtle Callaghan & Co’s GoodRx Holdings GDRX Stock Holding History

Hirtle Callaghan & Co’s Portfolio GDRX Stock Details GDRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$35.8K Hold
18,261
– – ﹤0.01% 112
2025
Q4 		$49.5K Buy
18,261
+6,869
+60% +$22.6K ﹤0.01% 110
2025
Q3 		$48.2K Buy
+11,392
New +$50.1K ﹤0.01% 100

Other funds holding GDRX

FPM
Francisco Partners Management San Francisco, California $292M AUM 34.13% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SLG
Silver Lake Group Menlo Park, California $3.68B AUM 7.22% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
PTC
Petrus Trust Company Dallas, Texas $915M AUM 2.95% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
PGCM
Prescott Group Capital Management Tulsa, Oklahoma $1B AUM 51.95% 1-Year Est. Return

Hirtle Callaghan & Co's GDRX Position: Q1 2026 in Review

Hirtle Callaghan & Co held its GoodRx Holdings (GDRX) position steady in Q1 2026 at 18,261 shares worth $35.8K. The position accounts for ﹤0.01% of the portfolio, ranked #112.

Hirtle Callaghan & Co first reported a position in GDRX in Q3 2025 and has held it in 3 quarters since. The position peaked at $49.5K in Q4 2025. 174 funds tracked by Wall St. Rank hold GDRX as of Q1 2026.

  • Hirtle Callaghan & Co held 18,261 shares of GoodRx Holdings worth $35.8K as of Q1 2026.
  • Hirtle Callaghan & Co left its GoodRx Holdings share count unchanged in Q1 2026.
  • GoodRx Holdings made up ﹤0.01% of Hirtle Callaghan & Co's portfolio in Q1 2026, its #112 holding.
  • Hirtle Callaghan & Co first reported a position in GoodRx Holdings in Q3 2025 and has held it in 3 quarters since.
  • Hirtle Callaghan & Co's GoodRx Holdings position peaked at $49.5K in Q4 2025.
  • 174 funds tracked by Wall St. Rank held GoodRx Holdings as of Q1 2026.

Based on Hirtle Callaghan & Co's 13F filing for Q1 2026, filed 13 May 2026.